N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?
GW Albers, MP Goldberg… - Annals of Neurology …, 1989 - Wiley Online Library
GW Albers, MP Goldberg, DW Choi
Annals of Neurology: Official Journal of the American Neurological …, 1989•Wiley Online LibraryAntagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer
a new approach for the treatment of ischemic brain injury. This strategy is supported by a
well‐developed scientific foundation and encouraging results in a variety of in vivo and in
vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan,
dextromethorphan, and ketamine, have already been used at low doses in humans for other
indications and are potential candidates for Phase I clinical trials.
a new approach for the treatment of ischemic brain injury. This strategy is supported by a
well‐developed scientific foundation and encouraging results in a variety of in vivo and in
vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan,
dextromethorphan, and ketamine, have already been used at low doses in humans for other
indications and are potential candidates for Phase I clinical trials.
Abstract
Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.
Wiley Online Library